Distribution of values of indicators of minimum suppressive concentrations of antibiotics in relation to gram-negative bacterial strains isolated from cystic fibrosis

Introduction. Cystic fibrosis is a severe chronic genetic disease, in which the microbiological status of the patient plays an important role, because it will determine the severity of the respiratory infection. In recent years, representatives of non-fermenting gram-negative bacteria (NFGNB) - P. aeruginosa, B. cenocepacia, Axylosoxidans; as well as representatives of the order Flavobacteriales - have become of great clinical importance in patients with cystic fibrosis. A feature of some representatives of NFGNB is the formation of resistance to antibacterial drugs, due to prolonged antimicrobial therapy. In addition to the acquired, there is a high level of natural resistance, and therefore the possibilities of using antibacterial drugs are significantly limited.

Aim. To estimate the distribution of the values of the minimum suppressive concentrations (MSC) of cefepim / sulbactam, piperacillin / tazobactam, biapenem in relation to 100 strains of Gram-negative bacteria isolated from respiratory samples from patients with cystic fibrosis.

Materials and methods. To date, new compounds have appeared with potential activity against the strains under consideration - cefepim / sulbactam, piperacillin / tazobactam, biapenem. We selected 100 bacterial strains isolated from respiratory samples from patients with cystic fibrosis from various regions of the Russian Federation. Among them, 69 strains are Pseudomonas aeruginosa, 6 - Achromobacter xylosoxidans, 14 - Burkholderia cenocepacia, 10 - Chryseobacterium spp., 1 - Elizabethkingia miricola. MSC values were determined for 3 antimicrobial drugs: cefepim / sulbactam, piperacillin / tazobactam, biapenem.

Results and discussions. According to the data obtained, it was found that most strains of Pseudomonas aeruginosa, Achromobacter xylosoxidans have a high level of sensitivity to cefepim/sulbactam, piperacillin/tazobactam. The criteria for evaluating the MSC indicators of the studied drugs in relation to Burkholderia cenocepacia and representatives of the order Flavobacteriales have not been determined, however, it is worth noting that most isolates have demonstrated an achievable value of MSC indicators. This suggests the possibility of practical application of antimicrobial drugs under test.

Conclusions. The data obtained indicate the microbiological efficacy of the drugs: cefepim/sulbactam, piperacillin/tazobactam, biapenem relative to NFGNB isolated from patients with cystic fibrosis.

1. Kondratyeva EI, Voronkova AYu, Kashirskaya NYu, Krasovsky SA, Starinova MA, Amelina EL et al. Russian registry of patients with cystic fibrosis: lessons and perspectives. Pulmonologiya. 2023;33(2):171-181. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-2-171-181.

2. Tronza TV, Voronkova AYu, Fedotova Nya, Fatkhullina IR, Tivanova EV, Ploskireva AA et al. The frequency and sensitivity to antimicrobial drugs of Staphylococcus aureus and Pseudomonas aeruginosa isolates from the lower respiratory tract in children with cystic fibrosis. Infectious Diseases: News, Opinions, Training. 2023;12(1):62-68. (In Russ.) https://doi.org/10.33029/2305-3496-2023-12-1-62-68.

3. Avetisyan LR, Shaginyan IA, Chernukha MYu, Burmistrov EM, Medvedeva OS, Rusakova EV et al. Directions of epidemiological surveillance of chronic lung infections caused by Burkholderia cepacia complex, Achromobacter spp., Pseudomonas aegidinosa and methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Epidemiologiya i Vaktsinoprofilaktika. 2020;19(1):14-23. (In Russ.) https//doi.org/10.31631/2073-3046-2020-19-1-14-23.

4. Zubova KV. The order Flavobacteriales: ecological features and clinical signify-cance in the development of human pathology: review. Bulletin of the Perm University. Ser. Biology. 2023;(1):58-64. (In Russ.) https://doi.org/10.17072/1994-9952-2023-1-58-64.

5. Jia S, Taylor-Cousar JL. Cystic Fibrosis Modulator Therapies. Annu Rev Med. 2023;74:413-426. https://doi.org/10.1146/annurev-med-042921-021447.

6. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implication for treatment. Curr Opin Pediatr. 2011;23(3):319-324. https://doi.org/10.1097/MOP.0b013e32834604f2.

7. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10(2):29-36. https://doi.org/10.1016/S1569-1993(11)60006-4.

8. Chebotar IV, Bocharova YuA, Mayansky NA. Mechanisms and regulation of antimicrobial resistance in Pseudomonas aeruginosa. Klinicheskaia Mikrobiologiia i Antimikrobnaia Khimioterapiia. 2017;19(4):308-319. (In Russ.) Available at: https://cyberleninka.ru/article/n/mehanizmy-rezistentnosti-pseudomonas-aeruginosa-k-antibiotikam-i-ih-regulyatsiya/viewer.

9. Kutsevalova OYu, Pokudina IO, Rozenko DA, Martynov DV, Kaminsky MYu. Modern problems of antibiotic resistance gram-negative nosocomial infections in the Rostov region. Medical Herald of the South of Russia. 2019;10(3):91-96. (In Russ.) https//doi.org/10.21886/2219-8075-2019-10-3-.

10. Lyamin AV, Zolotov MO, Kondratenko OV, Maksimova EA, Ismatullin DD, Bochkareva PV. Prevalence of antimicrobial-resistant Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. Meditsinskiy Sovet. 2023;17(20):114-120. (In Russ.) https//doi.org/10.21518/ms2023-346.

11. Yakovlev SV, Suvorova MP. Biapenem: clinical and microbiological characteristics and discussion of the place of the new carbapenem in the treatment of severe infections in the hospital. The point of view of clinical pharmacologists. Antibiotiki i Khimioterapiya. 2022;67(5-6):81-91. (In Russ.) https://doi.org/10.37489/0235-2990-2022-67-5-6-81-91.

12. Amelina EL, Krasovskiy SA, Usacheva MV, Krylova NA. Pathogenic treatment of cystic fibrosis: the first clinical case in Russia. Pulmonologiya. 2017;27(2):298-301. (In Russ.) https//doi.org/10.18093/0869-0189-2017-27-2-298-301.

13. Petrova NV, Kondratyeva EI, Krasovsky SA, Polyakov AV, Ivachshenko TE, Pavlov AE et al. National consensus project “Cystic fibrosis: definition, diagnostic criteria, treatment” Section “Genetics of cystic fibrosis. Molecular genetic diagnosis in cystic fibrosis”. Medical Genetics. 2016;15(11):29-45. (In Russ.) Available at: https://www.medgen-journal.ru/jour/article/view/188.

14. Gomon Yu M. Piperacillin-tazobactam: prospects for use in real clinical practice. Real Clinical Practice: Data and Evidence. 2023;3(3):1-7. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-36.

15. Yakovlev CV, Suvorova MP, Bykov AO, Zhuravel SV, Popugaev KA, Kulagina LYu et al. Open-Label, Multicenter, Observational Study of The Effectiveness of The Cefepime/Sulbactam Antibiotic (Maxictam®-AF) In Patients With Intra Abdominal Infection, Nosocomial Pneumonia or Ventilator-Associated Pneumonia (Study MAXI-2019). Antibiotiki i Khimioterapiya. 2020;65(11-12):49-58. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-11-12-49-58.